Last month, the German government passed a controversial cost-saving law that saw tens of thousands of patients denied access medical cannabis to flower reimbursed through statutory health insurance (GKV).
In the weeks since, a chaotic tug-of-war between physicians, health funds, patient groups and the cannabis industry has thrown the framework into further disarray.
Fissures have now opened between the country’s statutory-insurance physicians and the health funds, after an August move to soften the most contested provision, the mandatory six-month finished-medicine trial, which was itself reversed.
The question of how roughly 65,000 cannabis patients are actually treated now rests with a ministry that has yet to rule.
The Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-Beitragssatzstabilisierungsgesetz), a broad financial bill designed to reduce the country’s ballooning insurance deficit, officially took effect on July 30.
This removed dried flower from statutory reimbursement imposed a six-month finished-medicine trial before extracts like dronabinol or nabilone could be prescribed.
Amid a flood of queries from doctors, the KBV and the GKV-Spitzenverband issued a joint interpretation on August 06 that softened the rule.
In their statement, they suggested that the mandatory six-month trial would apply only to indications for which a finished medicine was actually licensed, and patients already on extracts would be spared. Industry and pharmaceutical bodies welcomed the move.
“The clarification provides legal certainty for physicians and, above all, for patients,” Philip Schetter, CEO of Cantourage Group SE, said in a press release. Continuity of treatment is an essential component of reliable medical care.”
On closer examination, though, the KBV changed its position once again. This week, it said that it now believed a cannabis finished medicine must be tried first in every case, even when it is not approved for the patient’s condition, which would mean prescribing ‘off-label’ medicines.
In practice, this means starting most patients on a product not licensed for their illness, which insurers normally reimburse only in exceptional cases. The four finished cannabis medicines approved for specific indications include Sativex for MS spasticity, Epidyolex for certain epilepsies, Canemes for chemotherapy nausea, and Exilby for chronic back pain.
Two exceptions still hold. Patients already on flower or extracts are unaffected. And if the finished medicine doesn’t work, or the patient can’t tolerate it, the doctor can switch straight to an extract, without seeing out the full six months or having to try a second finished product.
This policy maelstrom further complicates a situation pharmacists claim is already unworkable. High-concentration extracts for inhalation, the obvious replacement for flower, are not being reimbursed by all funds.
That leaves pharmacies exposed to ‘clawback’. Having already bought and dispensed an expensive extract, a pharmacy can later be refused payment by the insurer and left to absorb the cost, a risk that makes many wary of supplying at all. Meanwhile, individual funds and regional physicians’ associations are drawing contradictory conclusions from the same rules.
Felix Maertin, a Karlsruhe pharmacist who supplies many severely ill cannabis patients, has given the KBV and GKV-Spitzenverband a 14-day ultimatum to answer 15 questions and issue a public clarification, including whether they regard any extract above 25% THC as excluded from reimbursement and on what legal basis.
“Patients need a solution today, not in months or after the first social-court rulings,” he said. Another pharmacist has publicly called for a constitutional complaint, and a patient initiative is collecting video testimony to put before politicians.
Separately, the Arbeitsgemeinschaft Cannabis als Medizin (Working Group on Cannabis as Medicine) is already pursuing a constitutional complaint against the law at Karlsruhe.
To put the cannabis reimbursement issue into context, it’s worth briefly exploring Germany’s GKV funding gap. According to the latest GKV-Spitzenverband figures, spending rose around 8% in both 2024 and 2025, while contributory income grew only about 5% in 2025.
As costs continued to outpace contributions, the central health fund (Gesundheitsfonds) posted a combined deficit of nearly €10 billion in 2024, while reserves fell below the statutory minimum, and the health fund’s liquidity had to be propped up with a federal loan.
By 2030, Germany would be facing a structural gap of up to €40bn. By slashing flower from GKV, the government hoped to save roughly €130m, roughly one three-hundredth of the hole. Even on its most generous reading, including the additional cuts to extracts, the savings would have amounted to just 0.5% of the total deficit.
Because the approved indications are so narrow, a rule that forces a finished-medicine trial first, even off-label, widens the pool of patients who must be routed through those products.
Vertanical’s Exilby, a full-spectrum extract for chronic back pain with a neuropathic component, is due to launch in September. Sativex is licensed only for multiple-sclerosis spasticity.
Under the August 06 reading, Exilby would have been the mandatory first step for only a slice of pain patients. However, under the KBV’s new interpretation, a finished medicine must be tried first regardless of indication. Exilby has yet to agree to a reimbursed price with the Federal Joint Committee.
Pharma Deutschland, the country’s largest pharmaceutical industry association, had already warned that the underlying law was the problem. Its chief executive, Dorothee Brakmann, said the legislation had, ‘through its one-sided focus on short-term savings, caused operational problems that then had to be caught by interpretive notes and subsequent clarifications’, and predicted a further statutory correction would be needed.
The chaos of the last few weeks has so far proven Brakmann entirely correct.
For now, Germany’s medical cannabis framework rests on contested interpretations rather than settled rules. The decisive question is whether the Federal Ministry of Health (BMG) sides with the KBV’s tougher reading or the earlier joint interpretation, and whether it moves quickly enough to spare patients, prescribers and pharmacies another round of uncertainty.
Beyond that, the ACM’s constitutional challenge continues, and the doubt the insurers themselves raised in the spring, that a law designed to save money may not save it as patients migrate to reimbursed alternatives, remains unresolved.
The post Germany’s Medical Cannabis Insurance Reform Descends Into Chaos as Regulators Turn on Each Other appeared first on Business of Cannabis.
Continue reading...
In the weeks since, a chaotic tug-of-war between physicians, health funds, patient groups and the cannabis industry has thrown the framework into further disarray.
Fissures have now opened between the country’s statutory-insurance physicians and the health funds, after an August move to soften the most contested provision, the mandatory six-month finished-medicine trial, which was itself reversed.
The question of how roughly 65,000 cannabis patients are actually treated now rests with a ministry that has yet to rule.
Weeks of chaos
The Statutory Health Insurance Contribution Rate Stabilisation Act (GKV-Beitragssatzstabilisierungsgesetz), a broad financial bill designed to reduce the country’s ballooning insurance deficit, officially took effect on July 30.
This removed dried flower from statutory reimbursement imposed a six-month finished-medicine trial before extracts like dronabinol or nabilone could be prescribed.
Amid a flood of queries from doctors, the KBV and the GKV-Spitzenverband issued a joint interpretation on August 06 that softened the rule.
In their statement, they suggested that the mandatory six-month trial would apply only to indications for which a finished medicine was actually licensed, and patients already on extracts would be spared. Industry and pharmaceutical bodies welcomed the move.
“The clarification provides legal certainty for physicians and, above all, for patients,” Philip Schetter, CEO of Cantourage Group SE, said in a press release. Continuity of treatment is an essential component of reliable medical care.”
On closer examination, though, the KBV changed its position once again. This week, it said that it now believed a cannabis finished medicine must be tried first in every case, even when it is not approved for the patient’s condition, which would mean prescribing ‘off-label’ medicines.
In practice, this means starting most patients on a product not licensed for their illness, which insurers normally reimburse only in exceptional cases. The four finished cannabis medicines approved for specific indications include Sativex for MS spasticity, Epidyolex for certain epilepsies, Canemes for chemotherapy nausea, and Exilby for chronic back pain.
Two exceptions still hold. Patients already on flower or extracts are unaffected. And if the finished medicine doesn’t work, or the patient can’t tolerate it, the doctor can switch straight to an extract, without seeing out the full six months or having to try a second finished product.
READ MORE…
Germany Bans Cannabis Flowers from GKV and Mandates Six-Month Trial for Extracts
European Cannabis Insights Summit 2026: Patients & Politics Post-Reclassification
Germany’s Drug Commissioner Backs Cannabis Pilot Projects in Break With CDU Party Line
Pharmacists push back
This policy maelstrom further complicates a situation pharmacists claim is already unworkable. High-concentration extracts for inhalation, the obvious replacement for flower, are not being reimbursed by all funds.
That leaves pharmacies exposed to ‘clawback’. Having already bought and dispensed an expensive extract, a pharmacy can later be refused payment by the insurer and left to absorb the cost, a risk that makes many wary of supplying at all. Meanwhile, individual funds and regional physicians’ associations are drawing contradictory conclusions from the same rules.
Felix Maertin, a Karlsruhe pharmacist who supplies many severely ill cannabis patients, has given the KBV and GKV-Spitzenverband a 14-day ultimatum to answer 15 questions and issue a public clarification, including whether they regard any extract above 25% THC as excluded from reimbursement and on what legal basis.
“Patients need a solution today, not in months or after the first social-court rulings,” he said. Another pharmacist has publicly called for a constitutional complaint, and a patient initiative is collecting video testimony to put before politicians.
Separately, the Arbeitsgemeinschaft Cannabis als Medizin (Working Group on Cannabis as Medicine) is already pursuing a constitutional complaint against the law at Karlsruhe.
To put the cannabis reimbursement issue into context, it’s worth briefly exploring Germany’s GKV funding gap. According to the latest GKV-Spitzenverband figures, spending rose around 8% in both 2024 and 2025, while contributory income grew only about 5% in 2025.
As costs continued to outpace contributions, the central health fund (Gesundheitsfonds) posted a combined deficit of nearly €10 billion in 2024, while reserves fell below the statutory minimum, and the health fund’s liquidity had to be propped up with a federal loan.
By 2030, Germany would be facing a structural gap of up to €40bn. By slashing flower from GKV, the government hoped to save roughly €130m, roughly one three-hundredth of the hole. Even on its most generous reading, including the additional cuts to extracts, the savings would have amounted to just 0.5% of the total deficit.
A window for finished medicines
Because the approved indications are so narrow, a rule that forces a finished-medicine trial first, even off-label, widens the pool of patients who must be routed through those products.
Vertanical’s Exilby, a full-spectrum extract for chronic back pain with a neuropathic component, is due to launch in September. Sativex is licensed only for multiple-sclerosis spasticity.
Under the August 06 reading, Exilby would have been the mandatory first step for only a slice of pain patients. However, under the KBV’s new interpretation, a finished medicine must be tried first regardless of indication. Exilby has yet to agree to a reimbursed price with the Federal Joint Committee.
Pharma Deutschland, the country’s largest pharmaceutical industry association, had already warned that the underlying law was the problem. Its chief executive, Dorothee Brakmann, said the legislation had, ‘through its one-sided focus on short-term savings, caused operational problems that then had to be caught by interpretive notes and subsequent clarifications’, and predicted a further statutory correction would be needed.
The chaos of the last few weeks has so far proven Brakmann entirely correct.
What happens next
For now, Germany’s medical cannabis framework rests on contested interpretations rather than settled rules. The decisive question is whether the Federal Ministry of Health (BMG) sides with the KBV’s tougher reading or the earlier joint interpretation, and whether it moves quickly enough to spare patients, prescribers and pharmacies another round of uncertainty.
Beyond that, the ACM’s constitutional challenge continues, and the doubt the insurers themselves raised in the spring, that a law designed to save money may not save it as patients migrate to reimbursed alternatives, remains unresolved.
The post Germany’s Medical Cannabis Insurance Reform Descends Into Chaos as Regulators Turn on Each Other appeared first on Business of Cannabis.
Continue reading...
